🟢 Biovie is trading 7% up on October 16, 2026 with no confirmed catalyst

Biovie is trading at $1.21, up 7.08%, with no company-specific catalyst confirmed for the October 16 move.

• The latest company announcement, dated October 14, concerned planned presentations of Phase 2 findings at the American Neurological Association meeting, running October 17–20; it does not establish a reason for the rise.
• Biotech-sector and broader-market weakness provide context but do not explain Biovie’s gain.
• No trading-volume information was provided.